Principal Investigator: Dr. Robert Cotes
Criteria:
Purpose: This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness. Subjects will be screened at Visit 1, up to 30 days prior to randomization. At Visit 2, eligible subjects will be randomized (1:1) to ALKS 3831 or olanzapine and receive study drug for up to 12 weeks. The study will last for approximately 16 weeks.
Compensation: $50 for each study visit
Contact: Ayesha Khan (Study Coordinator)
Phone: 404-616-0853
Email: akhan31@emory.edu
Website link: https://clinicaltrials.gov/ct2/show/NCT03187769